What Concord Biotech does

Concord Biotech Limited is a vertically integrated biopharmaceutical company headquartered in Ahmedabad, Gujarat, India, specializing in the development, manufacturing, and commercialization of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished dosage formulations. Founded in 2000 by Sudhir Vaid, the company operates four manufacturing facilities across Gujarat — Units I (Dholka, API), II (Valthera, oral solid dosage formulations), III (Limbasi, API, described as one of the largest fermentation-based API plants in Asia), and IV (Valthera, injectable facility commissioned 2025) — supported by DSIR-certified R&D facilities in microbiology, fermentation, and formulation development. Its portfolio covers 30+ fermentation-based APIs across immunosuppressants (Tacrolimus, Mycophenolate Mofetil, Cyclosporine, Sirolimus), oncology (Temsirolimus, Everolimus, Doxorubicin), anti-bacterials (Mupirocin, Teicoplanin, Vancomycin, Daptomycin), and anti-fungals (Anidulafungin, Micafungin, Caspofungin, Amphotericin B), with combined fermentation capacity of 1,250 m³ and 802 million units/year of oral solid dosage capacity.

The company generates revenue through three streams: (i) API manufacturing and B2B sales to global pharmaceutical companies, (ii) finished formulations marketed globally (regulated markets via USFDA-approved ANDAs through subsidiary Stellon Biotech Inc. and generic formulations in emerging markets) and in India under branded generics under the INCA (critical care) and Conquest (nephrology, hematology, rheumatology) sub-brands, and (iii) Contract Research and Manufacturing Services (CRAM) offering strain improvement, media optimization, process development, and scale-up for fermentation and semi-synthetic products. Pricing is quote-based B2B with no public disclosure. Concord serves 250+ global customers across 70+ countries and holds regulatory approvals from USFDA, EU GMP, Japan PMDA, Brazil ANVISA, Korea MFDS, and others, enabling access to regulated and emerging markets.

Concord Biotech is publicly listed on BSE and NSE (ticker CONCORDBIO) since August 2023 and employs 501-1,000 people. The founder Sudhir Vaid serves as Chairman and Managing Director, with his son Ankur Vaid as Joint MD & CEO. The estate of late investor Rakesh Jhunjhunwala holds an estimated 24% stake (valued at approximately Rs 2,854 crore as of early 2026), making it the most significant external shareholder alongside Rare Enterprises (RARE Trusts). Recent strategic activity includes USFDA ANDA approvals in 2025-2026 for Teriflunomide, Mycophenolate Mofetil oral suspension, and Tofacitinib Tablets (targeting a combined ~$530M US market opportunity), the April 2026 acquisition of Celliimmune Biotech for entry into DNA engineering / cancer therapeutics, and renewable energy investments at the Limbasi and Dholka facilities.

Name

Concord Biotech

Legal name

Concord Biotech Limited

Website

https://concordbiotech.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Concord Biotech Limited is an India-based, publicly listed biopharmaceutical company that develops and manufactures fermentation-based APIs (immunospressants, oncology, anti-infectives) and finished formulations for global pharmaceutical companies across 70+ countries, operating four manufacturing facilities in Gujarat.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Active pharmaceutical ingredients
• Fermentation-based biopharmaceuticals
• Generic drug formulations
• Contract manufacturing services
• Immunosuppressant manufacturing

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. API Manufacturing & Sales: Manufacturing and selling fermentation-based Active Pharmaceutical Ingredients to global pharmaceutical companies. Products include immunosuppressants (Tacrolimus, Mycophenolate Mofetil, Cyclosporine), oncology drugs (Temsirolimus, Everolimus), anti-bacterials (Mupirocin, Teicoplanin), and anti-fungals (Anidulafungin, Micafungin). Revenue generated through direct B2B sales to pharmaceutical manufacturers across regulated and emerging markets.
2. Finished Formulations: Manufacturing and selling finished dosage forms including oral solids (tablets, capsules - 802 million units/year capacity), oral liquids, and injectables. Products marketed in India under own brands and distributed globally through partnerships in regulated and emerging markets.
3. Contract Research & Manufacturing (CRAM): Providing contract research and manufacturing services to global pharmaceutical companies. Services include strain improvement, media optimization, process development, scale-up, and manufacturing for fermentation and semi-synthetic products. Also offers formulation development and contract manufacturing for diverse dosage forms.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Concord Biotech Limited develops, manufactures, and commercializes fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations across immunosuppressants, oncology, anti-bacterials, and anti-fungals. The company operates four manufacturing facilities in Gujarat, India with 1,250 m³ combined fermentation capacity and 802 million units/year oral solid dosage capacity, supplying global pharmaceutical companies through direct B2B sales and USFDA-approved ANDAs. It also provides Contract Research and Manufacturing Services (CRAM) to pharmaceutical partners globally.

Product overview

Concord Biotech Limited is a biopharmaceutical company specializing in fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. The company operates four manufacturing facilities in Gujarat, India, with a combined fermentation capacity of 1,250 M3. Its product portfolio includes over 30 fermentation-based APIs across immunosuppressants (Tacrolimus, Mycophenolate Mofetil, Cyclosporine, Sirolimus), oncology (Temsirolimus, Everolimus, Doxorubicin), anti-bacterials (Mupirocin, Teicoplanin, Vancomycin, Daptomycin), and anti-fungals (Anidulafungin, Micafungin, Amphotericin B). The formulations business comprises Global Formulations (USFDA-approved ANDAs for regulated markets, generic formulations for emerging markets) and Branded Generic India products across Critical Care, Transplant/Immunology/Nephrology, and Rheumatology segments. The company also provides Contract Research & Manufacturing (CRAM) services through DSIR-certified R&D facilities. Products are sold in over 70 countries worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• INCA: Intensive care brand covering Antifungal, Antibiotics, and other critical care product portfolios for the Indian market.
• Conquest

Products and services

• Fermentation-based Active Pharmaceutical Ingredients (APIs) Niche fermentation and semi-synthetic APIs manufactured at the Dholka and Limbasi facilities with combined 1,250 m³ fermentation capacity. Sold to global pharmaceutical manufacturers across regulated markets (US, Europe, Japan) and emerging markets for use in finished drug formulations.
• Tacrolimus Capsules USP (0.5mg, 1mg, 5mg) Generic immunosuppressant capsule formulation for transplant patients, marketed in the US through Stellon Biotech Inc. subsidiary under USFDA ANDA approval.
• Mycophenolate Mofetil Capsules USP 250mg Generic immunosuppressant capsule used for prophylaxis of organ rejection in transplant recipients, marketed in the US through Stellon Biotech Inc.
• Mycophenolate Mofetil Tablets USP 500mg Generic immunosuppressant tablet for organ transplant patients, sold in the US market via Stellon Biotech Inc.
• Mycophenolic Acid DR Tablets USP (180mg, 360mg) Delayed-release generic immunosuppressant tablet formulation used for transplant patients, marketed in the US through Stellon Biotech Inc.
• Mycophenolate Mofetil for Oral Suspension USP 200 mg/mL Oral suspension formulation of immunosuppressant marketed through US subsidiary Stellon Biotech Inc.; targeted at transplant patient populations including pediatric patients.
• Tofacitinib Tablets (5mg, 10mg) Generic Janus kinase inhibitor tablet for autoimmune and inflammatory conditions, sold in the US market targeting a $500 million opportunity.
• Teriflunomide Tablets USP (7mg, 14mg) Generic immunomodulatory tablet for multiple sclerosis treatment, marketed in the US through Stellon Biotech Inc.
• Branded Generic India Products (INCA and INTRA portfolios) High-quality branded generic formulations tailored for the Indian healthcare market covering critical care, transplant, immunology, nephrology, and rheumatology segments. Marketed through domestic sales channels to Indian healthcare providers.
• Contract Research & Manufacturing (CRAM) Services Contract development and manufacturing services for global pharmaceutical companies covering API CRAM (fermentation, semi-synthesis, strain improvement, media optimization, process development, scale-up) and Formulation CRAM (pre-formulation, sterile/non-sterile dosage forms including oral solids, injectables, and lyophilized formulations) using DSIR-certified R&D facilities.

Quantifiable outcome

• Successfully completed ANVISA inspection at Limbasi API facility (June 8-12, 2026)
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered major and minor.

• Himachal Pradesh State GovernmentmajorStrategic or Co-development Partner · 13 August 2021MoU signed for setting up Rs. 500 crore fermentation-based API manufacturing plant in Una District, Himachal Pradesh. Represents significant capacity expansion initiative.
• Celliimmune Biotech Private LimitedminorStrategic or Co-development PartnerConcord Biotech acquired 100% of Celliimmune Biotech Private Limited for ₹66,00,000 to advance research in DNA engineering for cancer therapeutics.
• Palvella Therapeutics, Inc.minorStrategic or Co-development PartnerStrategic investment in US-based Palvella Therapeutics, Inc. for potential partnership and market expansion opportunities.
• AIIMS New DelhiminorOthersCSR partnership where Concord Biotech donated 2 electric SUVs to AIIMS for green energy initiative and patient transport between campuses.
• IKDRC-ITS (Institute of Kidney Disease & Research Centre)minorOthersCSR partnership for green initiative including development and maintenance of public park (Oxygen Garden) spanning approximately 75,000 sq.ft. with over 1,000 plants and shrubs.

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Biocon Limited: India-based biopharmaceutical company with a deep fermentation, biologics, and APIs business. Directly comparable to Concord's fermentation-based API and complex formulation focus, and an obvious Indian-headquartered peer for CRAM and immunosuppressant segments.
• Aurobindo Pharma: Large Indian generic manufacturer with substantial fermentation-derived API capacity and USFDA-approved sterile injectables. Overlaps with Concord on fermentation-based APIs (steroids, anti-infectives) and finished formulations across regulated markets.
• Dr. Reddy's Laboratories: India-headquartered global generics and API company with strong US presence and active pharmaceutical ingredient operations. Competes with Concord across immunosuppressants, anti-infectives, and other complex generic categories.
• Natco Pharma: Indian specialty generics company with oncology, immunosuppressant, and complex API focus. Comparable to Concord in niche complex generics and in competing for USFDA ANDA approvals in regulated therapeutic segments.

Broad incumbents

• Sun Pharmaceutical Industries: India's largest pharmaceutical company with a broad generics, specialty, and API portfolio including sterile injectables and fermentation-derived products. Operates as a much larger incumbent that overlaps with Concord in immunosuppressants and global generics.
• Lupin Limited: Large Indian generics and API manufacturer with USFDA-approved manufacturing. Overlaps with Concord in APIs and complex formulations across regulated and emerging markets; broader portfolio but similar regulated-market strategy.
• Recipharm: Global CDMO with sterile fill-finish and API capabilities. Comparable to Concord on the CRAM/formulation side for global pharma companies seeking outsourced sterile manufacturing.

Emerging players

• Piramal Pharma Solutions: CDMO arm of Piramal Pharma with strong contract development and manufacturing capabilities for APIs and sterile injectables. Direct competitor to Concord's CRAM business, particularly for fermentation and complex injectable CDMO engagements.

Regional players

• Strides Pharma Science: India-based specialty generics company focused on softgel, oral solids, and other regulated-market formulations. Comparable to Concord's formulation business in regulatory complexity and emerging/regulated market reach.

Others

• Sequent Scientific: Indian fermentation-based API and animal health manufacturer with significant fermentation capabilities. Adjacent peer sharing the fermentation platform technology paradigm relevant to Concord's API manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/concord-biotech-limited
• Facebookfacebook.com/ConcordBiotechIndia

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries6 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Concord Biotech